Brevan Howard Capital Management’s AnaptysBio ANAB Stock Holding History

Brevan Howard Capital Management’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$900K	Buy	13,329 +2,301	+21%	+$139K	0.01%	1125
2026 Q1	$612K	Buy	+11,028	New	+$593K	0.01%	1177
2025 Q4	–	Sell	-25,299	Closed	-$775K	–	1760
2025 Q3	$775K	Buy	25,299 +2,346	+10%	+$53.8K	﹤0.01%	1027
2025 Q2	$510K	Buy	22,953 +8,761	+62%	+$183K	﹤0.01%	1346
2025 Q1	$264K	Buy	+14,192	New	+$237K	﹤0.01%	907
2024 Q1	–	Sell	-9,673	Closed	-$207K	–	996
2023 Q4	$207K	Buy	+9,673	New	+$167K	﹤0.01%	869

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Brevan Howard Capital Management's ANAB Position: Q2 2026 in Review

Brevan Howard Capital Management increased its AnaptysBio (ANAB) stake by 21% in Q2 2026, buying an estimated $139K and bringing the position to 13,329 shares worth $900K. The position accounts for 0.01% of the portfolio, ranked #1125.

Brevan Howard Capital Management first reported a position in ANAB in Q4 2023 and has held it in 6 quarters since. 213 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

Brevan Howard Capital Management held 13,329 shares of AnaptysBio worth $900K as of Q2 2026.
Brevan Howard Capital Management bought 2,301 AnaptysBio shares in Q2 2026, an estimated $139K.
AnaptysBio made up 0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1125 holding.
Brevan Howard Capital Management first reported a position in AnaptysBio in Q4 2023 and has held it in 6 quarters since.
213 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.